Ticagrelor FDA approval issues revisited

Cardiology (Switzerland)

Volumn 122, Issue 3, 2012, Pages 144-147

  Serebruany, Victor L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trial; FDA; Regulatory approval; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIAC PATIENT; CORONARY ARTERY THROMBOSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FOOD AND DRUG ADMINISTRATION; GYNECOMASTIA; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; SINUS ARREST; STROKE;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL TRIALS, PHASE III AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG APPROVAL; HEMORRHAGE; HUMANS; MULTICENTER STUDIES AS TOPIC; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; TICLOPIDINE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84864098283     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000339470     Document Type: Article

References (11)

1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, PLATO Investigators: Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
2. Ticagrelor NDA letter of approval. http://www.accessdata.fda.gov/ drugsatfda-docs/appletter/2011/022433Orig1s000ltr.pdf.
3. Ticagrelor: Full prescribing information. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/022433s000lbl.pdf.
4. The FDA ticagrelor secondary review. http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM220192.pdf.
5. The FDA ticagrelor review of complete response. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022433Orig1s 000TOC.cfm.
6. The FDA ticagrelor statistical review. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/022433Orig1s000StatR.pdf.
7. The FDA ticagrelor summary review. http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/022433Orig1s000SumR.pdf.
8. The FDA ticagrelor pharmacology review(s). http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/022433Orig1s000PharmR. pdf.
9. The FDA ticagrelor chemistry review(s). http://www.accessdata.fda.gov/ drugsatfda-docs/nda/2011/022433Orig1s000ChemR. pdf.
10. Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
11. The FDA: What we do. http://www.fda.gov/aboutfda/whatwedo/default.htm.